GSK’s Luke Miels applies budget shock therapy to shake up the pharma group, refocus on blockbusters
The dramatic change of culture underway at GlaxoSmithKline is back on display this morning.
Reuters’ Ben Hirschler got wind of a demand from new pharma chief Luke Miels that his managers come up with 20% cost savings. They plan to devote the savings to concentrate more firepower on fewer products — part of the same “go big or go home” style that CEO Emma Walmsley is demanding on the R&D side of the business, which is looking to score near-term gains with a ramp-up on the oncology side.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.